June 15, 2020 / 4:58 PM / a month ago

BRIEF-Inventiva: Lanifibranor Meets Primary And Key Secondary Endpoints In Phase IIb NATIVE Clinical Trial

June 15 (Reuters) - INVENTIVA SA:

* INVENTIVA’S LANIFIBRANOR MEETS THE PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE IIB NATIVE CLINICAL TRIAL IN NON-ALCOHOLIC STEATOHEPATITIS (NASH

* LANIFIBRANOR ALSO MET KEY SECONDARY ENDPOINTS

* POSITIVE TOPLINE RESULTS SUPPORT DECISION TO MOVE FORWARD WITH CLINICAL DEVELOPMENT OF LANIFIBRANOR AND ENTER INTO PIVOTAL PHASE III DEVELOPMENT Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below